Abstract
Membrane type 1-matrix metalloproteinase (MT1-MMP, MMP-14) is associated with cancer invasion and metastasis leading to poor patient prognosis. MT1-MMP mediates cancer cell invasion via degradation of basement membrane and extracellular matrix, and induction of cell migration. However, MT1-MMP expression in the cancer stroma can drive invasion of carcinoma cells in vivo, suggesting MT1-MMP may also promote cancer invasiveness via paracrinemediated mechanisms. A major step in cancer cell metastasis is thought to be an epithelial-mesenchymal transition (EMT), in which carcinoma cells evolve from a stationary epithelial phenotype to a more motile mesenchymal phenotype. We demonstrate here that EMT is triggered by MT1-MMP-mediated activation of TGF-β signaling, involving induction of CUTL1 and subsequently, of Wnt5a. Mesenchymal-like cancer cells expressing endogenous MT1-MMP reverted to an epithelial phenotype when MT1-MMP, SMAD4, CUTL1, or Wnt5a expression or TGF-β activity was inhibited. Wnt5a knockdown in MT1- MMP expressing LNCaP cells caused decreased cell migration and cell growth in soft agar. While MT1-MMP expression did not affect total TGF-β level, MT1-MMP catalytic activity increased the availability of active TGF-β, enabling MT1-MMP-expressing cells to activate the EMT in nearby cells. MT1-MMP-expressing cells induced co-cultured non-MT1-MMP-expressing cells to undergo EMT by a TGF-β-dependent process. These results highlight a pathway by which tumor invasiveness may be expanded via MT1-MMP-mediated activation of TGF-β signaling, enabling autocrine and paracrine-mediated induction of EMT.
Keywords: MT1-MMP, EMT, TGF-β, CUTL1, prostate cancer.
Current Cancer Drug Targets
Title:MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Volume: 16 Issue: 7
Author(s): Hoang-Lan Nguyen, Pournima Kadam, Alex Helkin, Kevin Cao, Song Wu, Ghassan J. Samara, Qian Zhang, Stanley Zucker and Jian Cao
Affiliation:
Keywords: MT1-MMP, EMT, TGF-β, CUTL1, prostate cancer.
Abstract: Membrane type 1-matrix metalloproteinase (MT1-MMP, MMP-14) is associated with cancer invasion and metastasis leading to poor patient prognosis. MT1-MMP mediates cancer cell invasion via degradation of basement membrane and extracellular matrix, and induction of cell migration. However, MT1-MMP expression in the cancer stroma can drive invasion of carcinoma cells in vivo, suggesting MT1-MMP may also promote cancer invasiveness via paracrinemediated mechanisms. A major step in cancer cell metastasis is thought to be an epithelial-mesenchymal transition (EMT), in which carcinoma cells evolve from a stationary epithelial phenotype to a more motile mesenchymal phenotype. We demonstrate here that EMT is triggered by MT1-MMP-mediated activation of TGF-β signaling, involving induction of CUTL1 and subsequently, of Wnt5a. Mesenchymal-like cancer cells expressing endogenous MT1-MMP reverted to an epithelial phenotype when MT1-MMP, SMAD4, CUTL1, or Wnt5a expression or TGF-β activity was inhibited. Wnt5a knockdown in MT1- MMP expressing LNCaP cells caused decreased cell migration and cell growth in soft agar. While MT1-MMP expression did not affect total TGF-β level, MT1-MMP catalytic activity increased the availability of active TGF-β, enabling MT1-MMP-expressing cells to activate the EMT in nearby cells. MT1-MMP-expressing cells induced co-cultured non-MT1-MMP-expressing cells to undergo EMT by a TGF-β-dependent process. These results highlight a pathway by which tumor invasiveness may be expanded via MT1-MMP-mediated activation of TGF-β signaling, enabling autocrine and paracrine-mediated induction of EMT.
Export Options
About this article
Cite this article as:
Nguyen Hoang-Lan, Kadam Pournima, Helkin Alex, Cao Kevin, Wu Song, Samara J. Ghassan, Zhang Qian, Zucker Stanley and Cao Jian, MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/1568009616666160216125634
DOI https://dx.doi.org/10.2174/1568009616666160216125634 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging Perinatal Management of Fetal Tumors
Current Pediatric Reviews Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation
Endocrine, Metabolic & Immune Disorders - Drug Targets A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Development of Medical Images in Differentiating Benign from Malignant Thyroid Nodules
Current Medical Imaging Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Myristicin Suppresses Gastric Cancer Growth <i>via</i> Targeting the EGFR/ ERK Signaling Pathway
Current Molecular Pharmacology HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Application of Machine-learning based on Radiomics Features in Differential Diagnosis of Superficial Lymphadenopathy
Current Medical Imaging Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Micro-CT Assessments of Potential Anti-Osteoporotic Agents
Current Drug Targets MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology